血清α-HBDH、SE-CAD水平检测对急性髓系白血病患者化疗预后的预测价值

承德医学院学报 ›› 2025, Vol. 42 ›› Issue (1): 17-20.

血清α-HBDH、SE-CAD水平检测对急性髓系白血病患者化疗预后的预测价值

马彩翼, 赵小强^*, 冯佳楠, 邱少佳

河南科技大学第一附属医院血液内科,河南洛阳 471000

收稿日期:2024-04-11 出版日期:2025-02-10 发布日期:2025-02-24
通讯作者: *
基金资助:
河南省医学科技攻关计划(联合共建)项目（LHGJ20190547）

The Predictive Value of Serum α-HBDH Combined Detection SE-CAD Levels for Chemotherapy Prognosis in Patients with Acute Myeloid Leukemia

MA Cai-yi ZHAO Xiao-qiang FENG Jia-nan QIU Shao-jia MA Cai-yi, ZHAO Xiao-qiang^*, FENG Jia-nan, QIU Shao-jia

Hematology Department, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, 471000, China

Received:2024-04-11 Online:2025-02-10 Published:2025-02-24

摘要/Abstract

摘要： 目的分析血清α羟丁酸脱氢酶（α-HBDH）、可溶性E钙粘蛋白（SE-CAD）水平联合检测对急性髓系白血病（AML）患者化疗预后的预测价值。方法选取河南科技大学第一附属医院2021年1月~2023年6月收治的86例AML患者为研究组,另选取同期86名健康体检者为对照组。AML患者通过地西他滨治疗3个周期后,评估患者临床疗效分为完全缓解（n=28）、部分缓解（n=37）和未缓解（n=21）,并进行为期9个月的随访观察,分为预后良好患者（n=65）及预后不良患者（n=21）。对比2组及不同床疗效及预后患者入院时血清α-HBDH、SE-CAD水平,采用接受者操作特性（ROC）分析入院时血清α-HBDH、SE-CAD水平联合检测对AML患者化疗预后的预测价值。结果研究组入院时血清α-HBDH、SE-CAD水平显著高于对照组（P<0.05）;入院时血清α-HBDH、SE-CAD水平比较,完全缓解<部分缓解<未缓解（P<0.05）;预后不良患者入院时血清α-HBDH、SE-CAD水平显著高于预后良好患者（P<0.05）;入院时血清α-HBDH、SE-CAD水平单独及联合预测预后不良的曲线下面积（AUC）分别为0.642、0.674、0777,二者联合检测显著高于各指标单独检测。结论血清α-HBDH、SE-CAD水平与AML患者临床疗效及预后相关,通过检测其水平对临床评估患者疗效及预后具有一定指导作用,可作为AML预后评估的辅助指标。

关键词: α羟丁酸脱氢酶, 可溶性E钙粘蛋白, 急性髓系白血病, 化疗预后

Abstract: Objective To analyze the predictive value of α-Hydroxybutyrate dehydrogenase (α-HBDH) combined detection soluble E-cadherin (SE-CAD) levels for chemotherapy prognosis in patients with acute myeloid leukemia (AML). Methods A total of 86 patients with AML admitted to the First Affiliated Hospital of Henan University of Science and Technology from January 2021 to June 2023 were selected as the study group, and another 86 healthy individuals who underwent physical examinations during the same period were selected as the control group. After three cycles of decitabine treatment, patients with AML were divided into complete remission (n=28), partial remission (n=37) and non remission (n=21), and patients were divided into good prognosis (n=65) and poor prognosis (n=21) followed up for 9 months. The levels of serum α-HBDH and SE-CAD were compared in patients with different treatment outcomes and prognosis at admission between the two groups. The predictive value of combined detection of serum α-HBDH and SE-CAD levels on the prognosis of AML patients undergoing chemotherapy was analyzed using receiver operating characteristic (ROC) analysis. Results The levels of serum α-HBDH and SE-CAD in the study group were significantly higher than those in the control group at admission (P<0.05). Upon admission, the levels of serum α-HBDH and SE-CAD were compared, with complete remission < partial remission < no remission (P<0.05). The levels of serum α-HBDH and SE-CAD in patients with poor prognosis were significantly higher than those in patients with good prognosis at admission (P<0.05). The area under the curve (AUC) of serum α-HBDH and SE-CAD levels alone and in combination for predicting poor prognosis at admission were 0.642, 0.674, and 0.777, respectively. The combined detection of the two indicators was significantly higher than the detection of each indicator alone. Conclusion The levels of serum α-HBDH and SE-CAD are correlated with the clinical efficacy and prognosis of patients with AML. The detection of their levels have a certain guiding role in the clinical evaluation of the efficacy and prognosis of patients, and can be applied as an auxiliary index for the prognosis evaluation of AML.

Key words: α-Hydroxybutyrate dehydrogenase, Soluble E-cadherin, Acute myeloid leukemia, Chemotherapy prognosis

中图分类号:

R733.71

马彩翼, 赵小强, 冯佳楠, 邱少佳. 血清α-HBDH、SE-CAD水平检测对急性髓系白血病患者化疗预后的预测价值[J]. 承德医学院学报, 2025, 42(1): 17-20.

MA Cai-yi, ZHAO Xiao-qiang, FENG Jia-nan, QIU Shao-jia. The Predictive Value of Serum α-HBDH Combined Detection SE-CAD Levels for Chemotherapy Prognosis in Patients with Acute Myeloid Leukemia[J]. Journal of Chengde Medical University, 2025, 42(1): 17-20.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: http://tougao.cdmc.edu.cn:8088/CN/

http://tougao.cdmc.edu.cn:8088/CN/Y2025/V42/I1/17

参考文献

[1] Sincan S, Sincan G, Aşkın S, et al.Evaluation of Serum Paraoxonase, Myeloperoxidase, and HDL-Cholesterol Levels in Acute Myeloid Leukemia[J]. Inflammation, 2023, 46(6): 2470-2476.
[2] 张江召,刘敏,黄知平. 基于决策曲线分析血清TGF-β1、EGFR水平对急性髓系白血病患者大剂量AraC治疗效果的影响[J]. 中国实验血液学杂志,2022,30(2):407-412.
[3] 赵莲,郑子阳,钟敏. 血清SE-CAD与Matriptase在急性髓系白血病患者中的表达水平及其临床意义[J]. 中国实验血液学杂志,2019,27(3):753-757.
[4] Yuan ZM, Wang LH, Chen C.Prognostic value of serum α-HBDH levels in patients with lung cancer[J]. World J Surg Oncol, 2023, 21(1): 78.
[5] 中华医学会血液学分会白血病淋巴瘤学组. 成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2023年版)[J]. 中华血液学杂志,2023,44(9):705-712.
[6] 龚艳杰,肖笛鸣,杨璐,等. 成人急性髓系白血病患者CD68、C反应蛋白、血小板计数与疗效的相关性研究[J]. 癌症进展,2023,21(5):508-511.
[7] 杨晗春,成斐,黄娟娟. 地西他滨联合低剂量CAG方案化疗对老年急性髓系白血病的疗效与预后分析[J]. 中国药物应用与监测,2022,19(4):222-225.
[8] Ren X, Tao Q, Wang H, et al.Monocytic Myeloid-Derived Suppressor Cells But Not Monocytes Predict Poor Prognosis of Acute Myeloid Leukemia[J]. Turk J Haematol, 2022, 39(4): 230-236.
[9] Schwarzbich MA, Dai H, Kordelas L, et al.Pre-Transplant Serum Leptin Levels and Relapse of Acute Myeloid Leukemia after Allogeneic Transplantation[J]. Int J Mol Sci, 2022, 23(4): 2337.
[10] Zhao L, Zheng ZY, Zhong M.Expression level and Clinical Significance of Serum SE-CAD and Matriptase in Patients with Acute Myeloid Leukemia[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2019, 27(3): 753-757.
[11] 袁媛,李佳佳,王蒙,等. 急性髓系白血病患者血清SE-CAD、sPD-L1、MIP-1α水平与临床疗效及预后的关系研究[J]. 现代生物医学进展,2022,22(3): 570-573.
[12] 赵晶晶,张敏,林志强,等. VEGF、α-HBDH和β2-微球蛋白在儿童急性白血病诊断及预后中的价值[J]. 中国实验诊断学,2023,27(9): 1054-1056.
[13] 张新荣. 血清SDF-1、α-HBDH水平与老年急性髓系白血病患者中西医结合治疗预后的相关性[J]. 中国老年学杂志,2022,42(2): 312-315.
[14] 叶萍,裘玲玲,方丽娟. 血清sHLA-G、ɑ-HBDH和STAT1在急性髓系白血病中的表达意义及与预后的关系研究[J]. 中国基层医药,2022,29(8): 1168-1172.